Unity Biotechnology (stock symbol: UBX) Logo in transparent PNG and SVG formats

Unity Biotechnology Logo large

Unity Biotechnology Logo icon format

Unity Biotechnology Logo large for dark backgrounds

Unity Biotechnology Logo icon format for dark backgrounds

About Unity Biotechnology

Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase II clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy. It also develops UBX1967 for the treatment of ophthalmologic diseases; UBX2050, a human anti-Tie2 agonist monoclonal antibody for the treatment of age-related eye diseases; and UBX2089, a a-Klotho hormone drug candidate for multiple neurology indications. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was incorporated in 2009 and is headquartered in South San Francisco, California.

  • Website domain: unitybiotechnology.com
  • Employees: 65
  • Marketcap: $40.44 Million USD

Page last updated on:

August 14th, 2022

Categories: